E

New developments in the KRAS landscape

An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.

October 15, 2020
E

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
E
Hubble Space Telescope, Spitzer Space Telescope

On black holes and rising supernova stars in oncology

Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds

October 6, 2020
E

Marseille Immunopôle PIONeeR Project provides insights at ESMO20 into Lung Cancer Immunotherapy

Commentary on data presented at ESMO20 for PIONeeR Lung Cancer Immunotherapy Project

October 1, 2020
E

A phoenix rises from the ashes

A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape

September 23, 2020
E

Important learnings from ESMO20

Surprising new developments in early stage breast and metastatic prostate cancers

September 21, 2020
E
Flashing Red Light on Level Crossing

ESMO20 Un train peut en cacher un autre

Reflections on data in early breast cancer and NSCLC presented on Sunday at #ESMO20

September 21, 2020
E

Highlights of Super Saturday at ESMO20

Solid tumour highlights from ESMO not including breast cancer

September 20, 2020
E
TDF London 2014

Why Saturday at ESMO20 is like the Tour de France

Breast cancer highlights from Saturday at ESMO20

September 20, 2020
E

Highlights from Mini Oral Sessions at ESMO20

Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions

September 19, 2020
E

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020
E

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Five IO areas in early stage development to watch out for at ESMO20

September 15, 2020
E

ESMO20 Preview 2 – New Targets, New Opportunities

Can we predict the future cancer drug combinations from emerging new targets?

September 10, 2020
E

ESMO20 Preview 1 – Key progress in biomarker development

A look at progress and new developments in cancer biomarker developments

September 9, 2020